| Prev Close | 2.20 |
| Open | 2.20 |
| Day Low/High | 2.00 / 2.25 |
| 52 Wk Low/High | 4.08 / 15.01 |
| Volume | 28.24M |
| Avg Volume | 16.17M |
| Exchange | NASDAQ |
| Shares Outstanding | 271.19M |
| Market Cap | 618.31M |
| EPS | -0.60 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
5 Big-Volume Stocks to Add to Your Buy List -- Plus 2 to Avoid
Here's a technical look at how to trade some of the most active stocks on the market right now.
Twitter, Intel, Starbucks: Doug Kass' Views
Doug Kass shares his thoughts on what goes on his best ideas list and what's still moving down.
Underlying Risks in Speculative Biotechs; Trump Speaks, Bonds Slide : Best of Kass
In highlights from this week's trading diary and posts, Kass tells us about underlying risks in speculative biotechs and how Donald Trump's voice makes bonds slide.
Novavax's Steep Decline Underlines Small-Cap Biotech Risk
But we remain committed to our position in TherapeuticsMD.
Novavax (NVAX) Stock Tumbles on Vaccine Trial Failure, Ratings Downgrades
Novavax (NVAX) stock rating was reduced at several firms this morning after the company's RSV-F vaccine didn't achieve its primary and secondary endpoints in a clinical trial.
Analysts' Actions -- Citigroup, Comerica, Novavax, PepsiCo and More
Here are Friday's top research calls, including downgrades for Citigroup and Novavax, an upgrade Comerica and new coverage of PepsiCo.
Novavax (NVAX) Stock Tanking in After-Hours Trading on Vaccine Trial Failure
Novavax (NVAX) announced late Thursday that its RSV-F vaccine for lower respiratory tract disease did not meet its objectives in a clinical trial.
'Mad Money' Lightning Round: Lockheed Martin Can Fly to $210
Cramer says McCormick is up too much and he's not chasing Clayton Williams Energy.
Jim Cramer's 'Mad Money' Recap: The Urge to Merge Rules Wall Street
There are too many companies in just about every sector of this market, Cramer says.
Novavax (NVAX) Stock Dropping as Q2 Results Miss Expectations
Novavax (NVAX) reported a larger-than-anticipated loss and weak revenue for the 2016 second quarter.
How Will Novavax (NVAX) Stock React After Q2 Miss?
Novavax (NVAX) revenue declined 82% year-over-year for the second quarter.
Novavax (NVAX) Showing Signs Of A Dead Cat Bounce Today
Trade-Ideas LLC identified Novavax (NVAX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Novavax (NVAX) Is Today's Strong On High Volume Stock
Trade-Ideas LLC identified Novavax (NVAX) as a strong on high relative volume candidate
Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan
The markets took Friday's weak employment number pretty well, so Cramer's game plan focuses on a weaker U.S. dollar.
'Mad Money' Lightning Round: Take General Mills Over Kellogg
Cramer says VF is doing a terrific job but he's avoiding China Mobile.
